跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Propagermanium
首页
药物
Propagermanium
Investigational
Small Molecule
Propagermanium
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
技术标识符
化学式
C
6
H
10
Ge
2
O
7
CAS 编号
12758-40-6
UNII ID
1Q2P9TO9Q7
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
THERAPEUTIC FORMULATIONS FOR KIDNEY DISEASE COMPRISING REPAGERMANIUM OR PROPAGERMANIUM AND/OR AT1R BLOCKERS
EP 4709364 A1
申请人: DIMERIX BIOSCIENCE PTY LTD
优先权: 2023
EP
WO
2 件公开
Propagermanium for treating myeloma bone disease and other bone disorders
US 2003228263 A1
申请人: SURROMED INC
优先权: 2003
US
Compound medicine for treating hepatitis B virus and controlling HBV virus duplication
CN 1615883 A
申请人: LIU GUIKUN
优先权: 2004
CN
Oral disintegration tablets of Bingpazhe germanium for treating chronic hepatitis and its making method
CN 1911217 A
申请人: HEQUAN PHARMACEUTICAL CO LTD S
优先权: 2005
CN
MEDICINE FOR TREATING ADVANCED OR RECURRENT CANCER PATIENT BEING NON-RESPONSIVE OR NON-TOLERANT TO STANDARD CHEMOTHERAPY AND INCURABLE AND UNRESECTABLE
CN 110430885 A
申请人: HYOGO COLLEGE MEDICINE
优先权: 2017
CN
Polymer composite hydrogel for treating bladder tumors and preparation method of polymer composite hydrogel
CN 111529484 A
申请人: CHENGDU ZHIYA TECH CO LTD
优先权: 2020
CN
COMPOSITIONS COMPRISING A CHEMOKINE RECEPTOR PATHWAY INHIBITOR
US 20250049840 A1
申请人: DIMERIX BIOSCIENCE PTY LTD
优先权: 2022
US
药物
反馈